Description

**Delivery** 



## **PRODUCT INFORMATION**

TNF **Target** 

Tumor Necrosis Factor; Cachectin; TNF-**Synonyms** 

Alpha; Tumor Necrosis Factor Ligand Superfamily

Member 2;TNF-a;TNF;TNFA;TNFSF2

Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Gly57-Leu233 is

expressed with a 6His tag at the N-terminus.

In Stock P01375 **Uniprot ID** 

**Expression Host** E.coli

Tag C-6×His Tag

Molecular Characterization

Not available

**Molecular Weight** 21.8 KDa

Greater than 95% as determined by reducing **Purity** 

SDS-PAGE.

Formulation & Reconstitution

Background

Lyophilized from a 0.2  $\mu m$  filtered solution of 20mM PB, 100mM NaCl, pH 8.0.

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Storage & Shipping

Lyophilized proteins are shipped at ambient

temperature.

Tumor Necrosis Factor-a (TNF-a) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-a while cells that express CD8 secrete little or no TNF-a. Synthesis of TNF-a can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-a has been limited by the

proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic

toxicity has been of intense pharmacological interest. Human TNF-a that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receiptors. Based on these results, many TNF-a mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-a High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been


Email: info@dimabio.com

Website: www.dimabio.com

shown to have increased activity with less inflammatory side effects in vivó.

**Usage** Research use only

Conjugate Unconjugated










Figure 1. Greater than 95% as determined by reducing SDS-PAGE.

Email: info@dimabio.com Website: www.dimabio.com

